Andrew Kinloch

Andrew Kinloch is an accomplished scientist with extensive experience in immunology and platform innovation. Currently serving as Principal Scientist at both Flagship Pioneering and Ampersand Biomedicines since August 2021, Andrew previously held a position as Senior Scientist at Eutropics, where leadership in assay development and next-generation platform initiatives was pivotal for advancing therapies in leukemia and solid tissue cancers. Andrew's career began with a long tenure at the University of Chicago, contributing to the characterization of patient-derived monoclonal antibodies during chronic inflammatory diseases. The academic journey includes a PhD in Immunology from Imperial College London, alongside research roles at prestigious institutions such as Harvard University and the University of Cambridge.